Skip to main content

Gannon Steven

In the past year, 1 open-market sale filing worth $640.5K and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$640.5K
1 filing
Net
−$640.5K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Gannon Steven as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

XENE Xenon Pharmaceuticals Inc.

Director3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 8, 2024 (view filing)Mar 71 dayGannon StevenDirectorSSale−13.0K$46.28−$601.6K−86.7%2.00K after4 lots
Jun 6, 2025 (view filing)Jun 51 dayGannon StevenDirectorSSale−3$30.48−$91.440.0%7.14K after
Aug 13, 2026 (view filing)4:33 PM ETAug 112 daysGannon StevenDirectorSSale−10.0K$64.06−$640.5K−84.2%1.87K after

FUSN Fusion Pharmaceuticals Inc.

Director4 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 17, 2021 (view filing)Aug 161 dayGannon StevenDirectorPPurchase+6.00K$8.10+$48.6KNew position6.00K after
Aug 20, 2021 (view filing)Aug 18-192 daysGannon StevenDirectorPPurchase+3.17K$8.05+$25.5K+52.8%9.17K after2 lots
Aug 23, 2021 (view filing)Aug 23Same dayGannon StevenDirectorPPurchase+2.83K$7.99+$22.6K+30.8%12.0K after
Aug 11, 2022 (view filing)Aug 11Same dayGannon StevenDirectorPPurchase+44.4K$2.03+$90.1K+370.0%56.4K after